Genprex

Category: Press Releases

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed

Read More

Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System

Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at the 2023 American Association of Cancer Research (AACR) annual meeting

Read More

Genprex to Participate and Present at Upcoming May Industry and Investor Conferences 

Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More


Independent Researchers Find That TUSC2, the Gene Delivered by Genprex’s REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Read More

Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options

Read More

Genprex to Present at Bioprocessing Summit Conference

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies

Read More

Genprex to Participate in March Investor and Industry Conferences 

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes

Read More

Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor

The gross proceeds from the offering are expected to be approximately $4 million, before deducting placement agent fees and other estimated offering expenses.

Read More

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline

Read More